Breaching the Cancer Fortress
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Pancreatic tumors are poorly vascularized, suggesting that new therapeutic strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The desmoplastic reaction has been implicated in limiting tissue distribution of small molecule therapies, thereby mediating resistance [11, 12].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [11]
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961
Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3281 · Cited by 694
Cited by
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Self-citationBiochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression
Shields, M. A., Dangi-Garimella, S., Redig, A. J., & Munshi, H. G. (2012) · Biochemical Journal · doi:10.1042/bj20111240 · Cited by 205
New biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.119 · Cited by 195
Dangi-Garimella, S., Krantz, S. B., Barron, M. R., Shields, M. A., Heiferman, M. J., Grippo, P. J., Bentrem, D. J., & Munshi, H. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1855 · Cited by 176
“The fibrotic reaction was recently shown to limit the delivery and efficacy of gemcitabine in a mouse model of pancreatic cancer (7, 8).”
Current concepts and novel targets in advanced pancreatic cancer
Michl, P., & Gress, T. M. (2013) · Gut · doi:10.1136/gutjnl-2012-303588 · Cited by 152
“Based on recent preclinical data in mouse models that will be discussed below in detail, it has been hypothesised that currently available cytotoxic drugs can not access tumour cells at an effective concentration due to the extensive hypovascular stroma reaction that acts as a fence around tumour cells protecting them…”
BackgroundModulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
“Many proangiogenic molecules including VEGF, fibroblast growth factor (FGF), and PDGF are overexpressed in tumors and involved in angiogenesis, which cause chaotic structural development in these newly formed tumor vessels (Goel et al., 2011).”
BackgroundPancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery
Li, J., Wientjes, M. G., & Au, J. L. ‐. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9181-5 · Cited by 124
Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer
Saito, R.-A., Micke, P., Paulsson, J., Augsten, M., Peña, C., Jönsson, P., Botling, J., Edlund, K., Johansson, L., Carlsson, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3644 · Cited by 93
Improving Delivery and Efficacy of Nanomedicines in Solid Tumors: Role of Tumor Priming
Wang, J., Lu, Z., Gao, Y., Wientjes, M. G., & Au, J. L.-S. (2011) · Nanomedicine · doi:10.2217/nnm.11.141 · Cited by 85
Okada, Y., Takahashi, N., Takayama, T., & Goel, A. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab011 · Cited by 87
Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer
Brancato, V., Comunanza, V., Imparato, G., Corà, D., Urciuolo, F., Noghero, A., Bussolino, F., & Netti, P. A. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.072 · Cited by 82
“Furthermore, the aberrant fibrotic reaction compresses vessels thus limiting perfusion with consequent poor drug delivery [25,26].”
Cuneo, K. C., Chenevert, T. L., Ben‐Josef, E., Feng, M. U.-S., Greenson, J. K., Hussain, H. K., Simeone, D. M., Schipper, M. J., Anderson, M. A., Zalupski, M. M., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.07.005 · Cited by 76
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Willumsen, N., Bager, C. L., Leeming, D. J., Smith, V., Karsdal, M. A., Dornan, D., & Bay‐Jensen, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-554 · Cited by 72
Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, C. H., Kraft, P. L., Stolzenberg‐Solomon, R. Z., Steplowski, E., Brotzman, M. J., Xu, M., Mudgal, P., Amundadottir, L. T., Arslan, A. A., Bueno-de-Mesquita, H. B., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-303477 · Cited by 67
Jiang, T., Zhang, B., Shen, S., Tuo, Y., Luo, Z., Hu, Y., Pang, Z., & Jiang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09458 · Cited by 68
Yang, C., Liu, Y., He, Y., Du, Y., Wang, W., Shi, X., & Gao, F. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.036 · Cited by 72
Drifka, C. R., Eliceiri, K. W., Weber, S. M., & Kao, W. J. (2013) · Lab on a Chip · doi:10.1039/c3lc50487e · Cited by 64
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation
Girelli, R., Prejanò, S., Cataldo, I., Corbo, V., Martini, L., Scarpa, A., & Claudio, B. (2015) · Radiology and Oncology · doi:10.1515/raon-2015-0013 · Cited by 64
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
den broeck, A. V., Gremeaux, L., Topal, B., & Vankelecom, H. E. J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-354 · Cited by 67
“The response rate of the xenograft tumours to gemcitabine (4 out of 7) was higher than the known response rate in human patients (lower than 20%), which may be due to the reduced stromal component in the xenografts, thus improving drug delivery to the tumour cells (see [3,4]).”
BackgroundNovel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00331 · Cited by 55
“In addition to PSCs, cancerassociated fibroblasts suppress blood vessel formation leading to the sparse vasculature, making drug delivery more difficult (Olson and Hanahan, 2009).”
BackgroundInflammation and pancreatic cancer: disease promoter and new therapeutic target
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0915-x · Cited by 57
Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer
Dalah, E. Z., Erickson, B. A., Oshima, K., Schött, D., Hall, W. A., Paulson, E. S., Tai, A., Knechtges, P., & Li, X. A. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.018 · Cited by 54
“The abundant growth of fibrotic tissue through secretion of collagen (protein) infiltrates and encases neoplasmscausing a remarkable dense extracellular matrix component [3], which limits the delivery of radiosensitizing systemic therapy and reduces the amount of oxygen available for radiation-induced free radical for…”
BackgroundTargeted Drug Delivery Systems for Pancreatic Cancer
Khare, V. R., Alam, N., Saneja, A., Dubey, R. D., & Gupta, P. N. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2036 · Cited by 48
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
Tachtsidis, A., McInnes, L. M., Jacobsen, N., Thompson, E. W., & Saunders, C. M. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9796-8 · Cited by 53
Zhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11546 · Cited by 41
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Kogure, H., Yagioka, H., Miyabayashi, K., Mizuno, S., Yamamoto, K., Mouri, D., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02311.x · Cited by 43
Chaudhuri, T. R., Straubinger, N. L., Pitoniak, R., Hylander, B. L., Repasky, E. A., Ma, W. W., & Straubinger, R. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0602 · Cited by 38
Membrane proteomic analysis of pancreatic cancer cells
Liu, X., Zhang, M., Go, V. L. W. B., & Hu, S. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-74 · Cited by 37
“Furthermore, hypoxia can drive genomic instability and lead to a more aggressive tumor phenotype [16,17], which may partially explain the highly metastatic nature of PDAC [18].”
BackgroundNakai, Y., Isayama, H., Sasaki, T., Takahara, N., Saito, K., Ishigaki, K., Hamada, T., Mizuno, S., Miyabayashi, K., Yamamoto, K., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1873-2 · Cited by 32
“Abundant desmoplastic change is one of the characteristics of pancreatic cancer and is believed to cause chemoresistance by creating the barrier to delivery of chemotherapeutics (Olson and Hanahan 2009).”
BackgroundYuan, W., Yang, D., Su, Q., Zhu, X., Cao, T., Sun, Y., Dai, Y., Feng, W., & Li, F. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603907 · Cited by 29
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy
Naguib, Y. W., & Cui, Z. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8739-0_11 · Cited by 29
Recio‐Boiles, A., Ilmer, M., Rhea, P. R., Kettlun, C. S., Heinemann, M. L., Ruetering, J., Vykoukal, J. V., & Alt, E. (2016) · Oncotarget · doi:10.18632/oncotarget.7066 · Cited by 30
“Early detection of this stroma-rich, desmoplastic neoplasm is challenging because of long symptom-free intervals [2].”
BackgroundMiyamoto, R., Oda, T., Hashimoto, S., Kurokawa, T., Inagaki, Y., Shimomura, O., Ohara, Y., Yamada, K., Akashi, Y., Enomoto, T., et al. (2016) · Cancer Science · doi:10.1111/cas.12888 · Cited by 26
Zhang, B., Wang, H., Jiang, T., Jin, K., Luo, Z., Shi, W., Mei, H., Wang, H., Hu, Y., Pang, Z., et al. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1452243 · Cited by 29
Lonergan, K. M., Chari, R., Coe, B. P., Wilson, I. M., Tsao, M., Ng, R. T., MacAulay, C. E., Lam, S. C., & Lam, W. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009162 · Cited by 26
Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Kiseleva, A. A., Korobeynikov, V. A., Nikonova, A. S., Zhang, P., Makhov, P. B., Deneka, A. Y., Einarson, M. B., Serebriiskii, I. G., Liu, H., Peterson, J. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3535 · Cited by 28
Translation in solid cancer: are size‐based response criteria an anachronism?
Fernandes, M., Rösel, D., & Brábek, J. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1207-5 · Cited by 20
Cheng, H., Merika, E., Syrigos, K., & Saif, M. W. (2011) · PubMed · Cited by 14
Acousto-chemical manipulation of drug distribution: In vitro study of new drug delivery system
Kawabata, K.-I., Maruoka, T., Asami, R., & Ashida, R. (2014) · Japanese Journal of Applied Physics · doi:10.7567/jjap.53.07kf28 · Cited by 11
Michel, A., Dinger, T. F., Santos, A. N., Pierscianek, D., Oppong, M. D., Ahmadipour, Y., Dammann, P. R., Wrede, K. H., Hense, J., Pöttgen, C., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04043-2 · Cited by 9
Venkatasubramanian, P. N. (2012) · Europe PMC (PubMed Central) · Cited by 10
Novel Agents and Future Prospects in the Treatment of Pancreatic Adenocarcinoma
Sarris, E., Syrigos, K., & Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1654 · Cited by 7
“Several studies support that hedgehog-secreted signaling proteins are overexpressed in both the stroma and cancer stem cells, leading to the formation of a dense desmoplastic stroma that surrounds cancer cells and blocks drug delivery, and even participate in the maintenance of cancer stem cells which may be involved…”
BackgroundPrediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases
Michel, A., Oppong, M. D., Rauschenbach, L., Dinger, T. F., Barthel, L., Pierscianek, D., Wrede, K. H., Hense, J., Pöttgen, C., Junker, A., et al. (2022) · Cancers · doi:10.3390/cancers14061437 · Cited by 6
“Two important aspects possibly contributing to the aggressiveness of breast cancer after breast-preserving surgery are the pan-resistance after initial therapy and the multi-drug resistance [76,77].”
BackgroundHaze, H., Sier, C. F. M., Vahrmeijer, A. L., & Vuijk, F. A. (2024) · Surgeries · doi:10.3390/surgeries5010007 · Cited by 5
Beyond isolated cells: microfluidic transport of large tissue for pancreatic cancer diagnosis
Das, R., Murphy, R. G., & Seibel, E. J. (2015) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2076833 · Cited by 4
“An optical COM was calculated for each intensity profile (image frame) and (3) tracked over the time course of the movie recording.”
BackgroundMethodInfluentialChopra, A., Zamora, R., Yoram Vodovotz, B., Hodges, J. C., Barclay, D. A., Brand, R. E., Simmons, R. L., Lee, K. K. W., Paniccia, A., Murthy, P., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000370 · Cited by 4
Das, R., Burfeind, C. W., Kramer, G. M., & Seibel, E. J. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2041106 · Cited by 4
“In this fashion, pressure drops were indirectly measured across any stage of the flow line using the hydraulic analog of Ohm's Law (V = iR), i.e. hydraulic analog for Ohm's Law Δ Pressure (Pa) = Q (mL/min) * Rhydraulic (3) Proc. of SPIE Vol. 8976 89760R-3”
BackgroundControlled induction of mechanical bioeffects with pulsed ultrasound and chemical agents
Kawabata, K.-I., Maruoka, T., Asami, R., & Ashida, R. (2013) · IEEE International Ultrasonics Symposium · doi:10.1109/ultsym.2013.0538 · Cited by 4
Stories of drug repurposing for pancreatic cancer treatment—Past, present, and future
Ilmer, M., Weniger, M., Nieß, H., Wu, Y. F., Zhang, C., Westphalen, C. B., Krüger, S., Angele, M. K., Werner, J. M., D’Haese, J. G., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00009-9 · Cited by 3
Olivari, A., Agnetti, V., & Garajová, I. (2023) · Current Oncology · doi:10.3390/curroncol30070475 · Cited by 3
“The peritumoral desmoplastic reaction further impedes angiogenesis, compromising the delivery of chemotherapeutic drugs to the tumor and leading to chemoresistance [29].”
BackgroundDas, R., Agrawal, A., Upton, M. P., & Seibel, E. J. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2041114 · Cited by 3
Dudley, A. C., & Bautch, V. L. (2015) · The Journal of Pathology · doi:10.1002/path.4526 · Cited by 2
“A cardinal feature of PDAC is the accumulation of a dense ‘fortress’ of desmoplastic stroma consisting of myofibroblasts, inflammatory cells, and extracellular matrix which contributes to their ‘rock hard’ texture and deficient vascularization [7].”
BackgroundDas, R., Nguyen, T.-M., Lim, S. D., O’Donnell, M. P., Wang, R. K., & Seibel, E. J. (2014) · IEEE Healthcare Innovation Conference (HIC) · doi:10.1109/hic.2014.7038927 · Cited by 1
Targeted siRNA Delivery Methods for RNAi-Based Therapies
Chen, D. (2013) · Scholarship@Western (Western University) · Cited by 3
Development of ADCs Using Molecular Imaging
Yasunaga, M., Manabe, S., Tsuji, A. B., Furuta, M., Ogata, K., Koga, Y., Fujiwara, Y., Saga, T., & Matsumura, Y. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.16-00255-3 · Cited by 1
Mechanisms of malignant and non-malignant angiogenesis using zebrafish models
Jensen, L. D. (2010) · Figshare
Hitting cancer where it hurts most
Kuiken, H. J. (2012) · Utrecht University Repository (Utrecht University)
The Effect of G-block on the Extracellular Matrix Barrier to Molecular Diffusion
Wøien, S. M. H. (2015) · BIBSYS Brage (BIBSYS (Norway))
Ernst, J. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5915
Genetische Veränderungen des sporadischen Mammakarzinoms
Arnold, N. (2010) · Springer eBooks · doi:10.1007/978-3-642-12681-9_6
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
Metadata
- Authors
- Olson, P., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Science
- Published
- 2009-06-12
- Volume
- 324
- Issue
- 5933
- Pages
- 1400-1401
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2063941572
- Cited by
- 62
- References
- 16
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 5 · 2014: 9 · 2013: 8 · 2012: 7
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- pancreatic tumors, tumor vascularization, tumor hypoxia, pancreatic cancer treatment, tumor microenvironment
- MeSH terms
- Gemcitabine, Animals, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease Models, Animal, Fibroblasts, Humans, Neoplasm Metastasis, Neoplasm Transplantation, Neovascularization, Pathologic, Pancreatic Neoplasms, Signal Transduction, Stromal Cells, Carcinoma, Pancreatic Ductal, Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.